Company news

Humacyte, Inc. news in 2026

Humacyte, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Humacyte Innovative Research in Coronary Bypass and Vascular Regeneration to be Highlighted at American Heart Association Scientific Sessions 2026

November 3, 2026

Humacyte To Announce 2026 Third Quarter Financial Results and Provide Business Update on November 10, 2026

November 2, 2026

Humacyte Strengthens Intellectual Property Portfolio with Issuance of New U.S. Patent Covering Symvess and Other Bioengineered Tissues

October 28, 2026

Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months Sooner

October 23, 2026

Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals

October 15, 2026

Humacyte Announces Phase 3 V012 Trial Results for ATEV in Women Requiring Hemodialysis Access Accepted for a Late-Breaking Session Presentation at ASN Kidney Week 2026

October 12, 2026

Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik

September 28, 2026

Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference

September 10, 2026

Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months

September 9, 2026

Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions

August 24, 2026

Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results

August 19, 2026

Board-Certified Vascular and Endovascular Surgeon Performs First Commercial Symvess® Implantation; Cites Bioengineered Blood Vessel as “Revolutionary Advancement”

August 18, 2026

Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update

August 12, 2026

Humacyte To Announce 2026 Second Quarter Financial Results and Provide Business Update on August 12, 2026

August 7, 2026

Humacyte Announces FDA Acceptance of IND for First-In-Human Clinical Study of CTEV for Coronary Artery Bypass Grafting

July 27, 2026

Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access

July 14, 2026

Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting

June 15, 2026

Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients

June 10, 2026

Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access

May 26, 2026

Humacyte Announces Symvess® is Now Under Contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs

May 20, 2026

Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update

May 12, 2026

Humacyte Appoints Dr. Todd E. Rasmussen as Chief Surgical Officer

May 12, 2026

Humacyte To Announce 2026 First Quarter Financial Results and Provide Business Update on May 13, 2026

May 8, 2026

Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026

April 27, 2026

Humacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess®

April 24, 2026

Humacyte Appoints Jim Mercadante as Chief Commercial Officer

April 21, 2026

Humacyte Announces Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess® for Vascular Trauma Repair

April 21, 2026

Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update

March 27, 2026

Humacyte Appoints Rick McElheny as Senior Vice President of Business Development

March 25, 2026

Humacyte To Announce 2025 Fourth Quarter and Year End Financial Results and Provide Business Update on March 27, 2026

March 23, 2026

Humacyte Receives Symvess® Purchase Commitment for Clinical Evaluation and Outreach Program in the Kingdom of Saudi Arabia

March 19, 2026

Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common Stock

March 18, 2026

Humacyte Submits Marketing Authorization Application for Symvess® in Israel for Vascular Trauma Repair

March 16, 2026

Humacyte To Participate in Upcoming Investor Conferences

March 2, 2026

Humacyte Announces Presentation of Symvess® Long-Term Safety and Efficacy Results at VESS Meeting

February 18, 2026

Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels

February 9, 2026

Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications

January 8, 2026

Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel

January 5, 2026

Calls in 2026

Decks in 2026